Analysis of KRAS mutations in colorectal cancer (CRC) patients by gender in a Brazilian cohort of 3,346 patients.

Ferreira, Carmen Verı́ssima; Zalcberg-Renault, Ilana; Vieira, F. M.; Bonamino, Martín; Zalis, Mariano

doi:10.1200/jco.2010.28.15_suppl.3614

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain studies have reported a higher frequency of KRAS mutations in females compared with males (18,27). This study had an almost equal ratio of males to females but identified no statistical difference in KRAS mutation with respect to gender.…”

Section: Discussioncontrasting

confidence: 40%

“…The frequency and spectrum of KRAS mutations did not differ when compared with those of most other studies (16)(17)(18)(19)(20)(21).…”

Section: Discussionmentioning

confidence: 51%

“…shown in Table V ( [16][17][18][19][20][21]. In most countries, the KRAS mutation rate ranged from 18-47%, as identified in Egypt and the United States, respectively.…”

Section: Mutated Wt Kras Kras --------------------------------------mentioning

confidence: 99%

See 2 more Smart Citations

KRAS mutations and subtyping in colorectal cancer in Jordanian patients

Elbjeirami

Sughayer

2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. Colorectal cancer (CRC) is one of the most common malignancies in the Western world and Jordan. v-Ki-ras2 Kirsten rat sarcoma (KRAS) mutations represent an early event in the development and progression of CRC. Previous studies have demonstrated that KRAS mutations serve as a predictor of response to EGFR-targeted therapies for patients with metastatic CRC. The aim of this study was to determine the portion of CRC patients with wild -type KRAS status and molecular subtypes of KRAS mutations in Jordan as compared with other countries. DNA was isolated from 100 consecutive colorectal carcinoma specimens from patients who underwent surgical resection or colonoscopic biopsies of colorectal tumors and had developed metastatic disease. KRAS mutations were detected by hybridization-based strip assay as well as RT-PCR-based assay and confirmed by standard Sanger sequencing of codon 12 and 13 of exon 1 of the KRAS gene. Among 100 tested patients, 56% had a wt-KRAS genotype and 44% had a mutated KRAS genotype. The pGly12Asp was the most commonly detected mutation (54.5%). KRAS mutations were independently associated with patient age, gender and tumoral variables. The ratio of mutated versus wt-KRAS patients in this study is similar to those reported in Western countries but contrasts to neighboring Middle Eastern countries. Colorectal carcinoma cases from Jordan had higher KRAS mutation frequencies compared with other Middle Eastern countries which is likely to reflect different molecular pathogenesis and environmental exposures.

show abstract

Section: Discussioncontrasting

confidence: 40%

“…The frequency and spectrum of KRAS mutations did not differ when compared with those of most other studies (16)(17)(18)(19)(20)(21).…”

Section: Discussionmentioning

confidence: 51%

See 1 more Smart Citation

KRAS mutations and subtyping in colorectal cancer in Jordanian patients

Elbjeirami

Sughayer

2012

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Codon The analysis of associations between the mutation status of the tumor and patient characteristics showed that KRAS mutations were significantly more frequent in females than in males (P = 0.02). A similar associa tion has been observed in other studies [35,36], although not always [37]. KRAS mutations were asso ciated with distant metastasis (P = 0.04) in our sample, while the difference in frequency of KRAS mutations between patients with or without metastasis was non significant (P = 0.38) in other studies [38].…”

Section: Discussionsupporting

confidence: 91%

Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients

et al. 2015

View full text Add to dashboard Cite

Somatic mutations of KRAS, PIK3CA, and BRAF cause insensitivity of colorectal tumors to ther apy with anti EGFR monoclonal antibodies, necessitating a genetic testing prior to therapy. A biological microchip was developed and validated to allow detection of 19 somatic mutations in KRAS, PIK3CA, and BRAF genes. The method combines LNA clamp PCR and allele specific hybridization on a microchip and detects mutant DNA in 100 times wild type background (1%). A total of 66 DNA samples isolated from col orectal tumors were tested with the biochip. Possible associations between the genetic status of the tumor and the patient's characteristics (age, sex, tumor localization, stage, and TMN) were assessed statistically. KRAS mutations were more common in females (P = 0.02) and in patients with distant metastasis (P = 0.04). Other associations between the presence of mutations and patient characteristics were not observed. The method proved highly sensitive and can be used in oncology to select patients who sensitive to therapy with anti EGFR monoclonal antibodies.

show abstract